Cancer Therapy News and Research

RSS

Nanoparticle could allow diagnosis and treatment in one visit

Researchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent dye and kills them with heat.

15 Dec 2009

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

A novel class of cancer therapies called live biologics is offering new hope for patients affected by hard-to-treat cancers, according to two different studies testing the therapies in patients with sarcomas and head and neck cancers.

14 Dec 2009

Study finds racial disparities in breast cancer care

Black women are less likely than white women to receive radiation therapy after a lumpectomy, the standard of care for early stage breast cancer, according to a new study by researchers at The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Interim results from a European clinical trial, RESTORE 2, demonstrate that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients.

14 Dec 2009

African American women with breast cancer receive no follow-up care after lumpectomy, shows study

A new study finds many breast cancer patients - particularly African American women - do not receive recommended radiation treatments after undergoing a lumpectomy.

14 Dec 2009

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher who led what is regarded to be a key clinical trial determining the best use of Herceptin.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Findings from three studies using bioTheranostics' breast cancer molecular test reported

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from three studies using the company's breast cancer molecular test.

14 Dec 2009

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.

14 Dec 2009

Positive interim results of ARRY-380 in Phase 1 trial announced

Array BioPharma Inc. today announced positive interim results of its novel, small molecule HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients.

13 Dec 2009

FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study

Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product “ATI-1123,” a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.

10 Dec 2009

Moderate consumption of alcoholic beverages increases the risk of breast cancer recurrence

Moderate consumption of alcoholic beverages (at least three to four drinks per week, no matter the type of alcohol) is associated with a 30 percent increased risk of breast cancer recurrence, according to a new Kaiser Permanente study. Post-menopausal or overweight women may be most susceptible to the effects of alcohol on recurrence, according to the researchers.

10 Dec 2009

YM BioSciences announces results of collaborative antibody development program

YM BioSciences Inc., today announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliMab(TM) technology, the program is designed to generate novel antibodies that target cell surface receptors associated with cancer, uniquely optimized to produce efficacy with reduced toxicities.

10 Dec 2009

Genetic variations in Sonic Hedgehog pathway associated with response to standard immunotherapy

Genetic variations in the Sonic Hedgehog pathway increase the likelihood of recurrence, reduce survival time and limit response to therapy for people with non-muscle invasive bladder cancer, scientists from The University of Texas M. D. Anderson Cancer Center reported today at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

10 Dec 2009

Varian Medical Systems receives IDG's InfoWorld 100 Award for innovative use of IT

Zenprise, Inc., a provider of mobile management software, today announced its customer, Varian Medical Systems Inc., received IDG's InfoWorld 100 Award based on its deployment of the Zenprise MobileManager platform. The InfoWorld 100 Awards recognizes the top 100 most innovative uses of IT initiatives to further business goals.

9 Dec 2009

GPEC receives unrestricted grant of $250,000 to study new treatments for breast cancer

Located at Vancouver General Hospital and a partner of the BC Cancer Agency, the Genetic Pathology Evaluation Centre, led by three prominent pathologists, is a recognized world leader in cancer research in the area of biomarker technology. Today, with an additional unrestricted grant of $250,000 from sanofi-aventis, GPEC is ready to make even more scientific breakthroughs.

9 Dec 2009

Immune-boosting drug: A new way for improving cancer treatment

Stimulating the body's own immune system to fight cancer offers new treatment opportunities for cancer patients, and scientists have made the first step towards finding existing drugs that could help.

9 Dec 2009

Scientists identify new potential drug for treating acute myeloid leukaemia

EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients' own 'natural killer' cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myeloma.

8 Dec 2009

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.

8 Dec 2009

Erbitux gaining market share of Avastin in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

8 Dec 2009

Cancer Therapy News and Research

Nanoparticle could allow diagnosis and treatment in one visit

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

Study finds racial disparities in breast cancer care

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

African American women with breast cancer receive no follow-up care after lumpectomy, shows study

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Texas researchers identify new detection method for circulating tumor cells

Findings from three studies using bioTheranostics' breast cancer molecular test reported

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

Positive interim results of ARRY-380 in Phase 1 trial announced

FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study

Moderate consumption of alcoholic beverages increases the risk of breast cancer recurrence

YM BioSciences announces results of collaborative antibody development program

Genetic variations in Sonic Hedgehog pathway associated with response to standard immunotherapy

Varian Medical Systems receives IDG's InfoWorld 100 Award for innovative use of IT

GPEC receives unrestricted grant of $250,000 to study new treatments for breast cancer

Immune-boosting drug: A new way for improving cancer treatment

Scientists identify new potential drug for treating acute myeloid leukaemia

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Erbitux gaining market share of Avastin in Europe

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News